Evidence map›Paper›PMID 31034002›Full record

Observational studyJAMA neurology2019

Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis.

Christiane Gasperi, Anke Salmen, Gisela Antony, Antonios Bayas, Christoph Heesen, Tania Kümpfel, Ralf A Linker, Friedemann Paul, Martin Stangel, Björn Tackenberg and 12 more

Abstract readObservational Study
In one paragraph

Observational study in JAMA neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed.

  1. Article
  2. CSF Proteins Associated With Neuroaxonal Damage in Early Active Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. B-Cell Receptor Repertoire: Recent Advances in Autoimmune Diseases.Clinical reviews in allergy & immunology · 2024
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Christiane GasperiDepartment of Neurology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Anke SalmenDepartment of Neurology, St, Josef Hospital, Ruhr-University Bochum, Bochum, Germany.
Gisela AntonyCentral Information Office German Competence Network of Multiple Sclerosis, Philipps University Marburg, Marburg, Germany.
Antonios BayasDepartment of Neurology, Klinikum Augsburg, Augsburg, Germany.
Christoph HeesenInstitute of Neuroimmunology and Multiple Sclerosis, Department of Neurology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Tania KümpfelInstitute of Clinical Neuroimmunology, Ludwig-Maximilians-Universität, Munich, Germany.
Ralf A LinkerDepartment of Neurology, University Hospital Erlangen, Erlangen, Germany.
Friedemann PaulNeuroCure Clinical Research Center, Charité-Univeritätsmedizin Berlin, Berlin, Germany.
Martin StangelClinical Neuroimmunology and Neurochemistry, Department of Neurology, Hannover Medical School, Hannover, Germany.
Björn TackenbergClinical Neuroimmunology Group, Department of Neurology, Philipps-University of Marburg, Marburg, Germany.
Florian Then BerghDepartment of Neurology, University of Leipzig, Leipzig, Germany.
Clemens WarnkeDepartment of Neurology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
Frank WeberMax Planck Institute of Psychiatry, Munich, Germany.
Heinz WiendlDepartment of Neurology University of Münster, Münster, Germany.
Brigitte WildemannDepartment of Neurology, University Hospital Heidelberg, Heidelberg, Germany.
Uwe K ZettlDepartment of Neurology, University of Rostock, Rostock, Germany.
Ulf ZiemannDepartment of Neurology & Stroke, Eberhard-Karls-Universität Tübingen, Tübingen, Germany.
Frauke ZippDepartment of Neurology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Hayrettin TumaniDepartment of Neurology, University of Ulm, Ulm, Germany.
Ralf GoldDepartment of Neurology, St, Josef Hospital, Ruhr-University Bochum, Bochum, Germany.
Bernhard HemmerDepartment of Neurology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
German Competence Network of Multiple Sclerosis

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Reliable biomarkers associated with disability worsening in multiple sclerosis (MS) are still needed. Objective: To determine a possible association of intrathecal IgG synthesis and early disability worsening as measured by Expanded Disability Status Scale (EDSS) scoring in patients with relapsing-remitting MS or clinically isolated syndrome. Design, Setting, and Participants: Cerebrospinal fluid measurements and clinical data from the observational longitudinal German national multiple sclerosis cohort were analyzed. Patients were recruited between August 2010 and November 2015 from 18 centers. Data analysis was completed from August 2018 to December 2018. Exposure: Patients were offered standard immunotherapies per national treatment guidelines. Main Outcomes and Measures: A possible association between intrathecal IgG synthesis and risk of EDSS worsening 4 years after study inclusion was tested as the primary end point by multivariable binomial regression analysis. Kaplan-Meier analysis with a log-rank test was used to assess the association of intrathecal IgG synthesis with the time to EDSS worsening. Associations between intrathecal IgM or IgA synthesis and other cerebrospinal fluid parameters and EDSS worsening were analyzed as exploratory end points. Data collection began before the hypotheses were formulated. Results: Of all 1376 patients in the German Competence Network of Multiple Sclerosis cohort, 703 patients were excluded owing to missing cerebrospinal fluid or EDSS data. Of the 673 included patients, 459 (68.2%) were women. The mean (SD) age at baseline was 34 (10) years. Intrathecal IgG synthesis was associated with a higher risk of EDSS worsening after 4 years (odds ratio, 2.02 [95% CI, 1.15-3.58]; P = .01), independent of the occurrence of relapses and disease-modifying therapy. Additionally, intrathecal IgG synthesis was associated with earlier EDSS worsening; 4 years after study entry, worsening occurred in 28.4% (95% CI, 22.7%-34.1%) and 18.1% (95% CI, 12.4%-23.9%) of patients with and without intrathecal IgG synthesis, respectively. No association of other routine cerebrospinal fluid parameters with EDSS worsening was found. Conclusions and Relevance: Patients with new diagnoses of relapsing-remitting multiple sclerosis or clinically isolated syndrome with intrathecal IgG synthesis had a higher risk of and shorter time to EDSS worsening across a 4-year period of follow-up. Intrathecal IgG synthesis is a potentially useful marker for disability worsening in patients with multiple sclerosis and may be useful for early treatment decisions.

Indexed as

AdultCohort StudiesDemyelinating DiseasesFemaleHumansImmunoglobulin AImmunoglobulin GImmunoglobulin MMaleMultiple Sclerosis, Relapsing-RemittingOligoclonal BandsProspective StudiesSeverity of Illness IndexImmunoglobulin AImmunoglobulin GImmunoglobulin MOligoclonal Bands

Identifiers

PMID31034002
PMCPMC6583696

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.